Molecular subtypes predict second breast events of ductal carcinoma in situ after breast‐conserving surgery. (22nd May 2022)

• Record Type: Journal Article
• Authors: Yang, Yilan; Zhao, Xu; Wang, Xuanyi; Jin, Kairui; Luo, Jurui; Yang, Zhaozhi; Mei, Xin; Ma, Jinli; Shao, Zhimin; Zhang, Zhen; Chen, Xingxing; Guo, Xiaomao; Yu, Xiaoli
• Is Part Of: Cancer medicine. Volume 11:Number 14(2022)
• Page Start: 2755
• Page End: 2766
• Publication Date: 2022-05-22
• Subjects: DCIS -- HER2 overexpression -- molecular subtypes -- second breast events; 616.994005
• DOI: 10.1002/cam4.4651
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Purpose: Currently, the prognostic value of molecular subtypes in ductal carcinoma in situ (DCIS) remains unclear. In this study, we explored whether molecular subtypes could predict second breast events (SBEs) in patients after breast‐conserving surgery (BCS). Methods: From January 2008 to December 2016, 291 DCIS patients treated with BCS were retrospectively analyzed. Patients were classified into four molecular subtypes: luminal A, luminal B, human epidermal growth factor receptor 2 (HER2) overexpression, and triple‐negative breast cancer (TNBC). The SBE incidence was calculated by the competing risk model and compared by Gray's test. The disease‐free survival rates were estimated by the Kaplan–Meier method and compared by the log‐rank test. Prognostic factors were evaluated by univariate and multivariate COX proportional hazards regression model. Results: With a median follow‐up of 66 months, 12 SBEs were identified. The 5‐year overall SBE incidence of luminal A, luminal B, HER2 overexpression, and TNBC was 2.18%, 4.25%, 15.15%, and 0.00%, respectively. In the univariate analysis, the HER2 overexpression subtype was the predictor of overall ( p = 0.005), in situ ( p = 0.004), and ipsilateral SBEs ( p = 0.008). Patients with endocrine therapy were less likely to develop in situ SBEs ( p = 0.039). Additionally, patients with closed (<2 mm) or involved margins were related to a higher risk of contralateral SBEs ( p = 0.029). In the multivariate analysis, the HER2 overexpression subtype remained of prognostic values for overall ( p = 0.006), in situ ( p = 0.029), and ipsilateral SBEs ( p = 0.012). Conclusions: The molecular subtype, especially the HER2 overexpression subtype, was the independent prognostic factor for DCIS patients who underwent BCS.